| |
Disease Foundation Forum - Invest In Cures
|
| With Chris Reyes (CEO, Bloom Science), Robert Bhisitkul (CMO, Oculinea), Daniel Chung (CMO, Sparing Vision), Wesley Jones (CEO, Vonova), Michael Kelly (Chief Scientific Officer, CureDuchenne), Tyler Mizenko (VP Biz Dev, Prendio), Mike Hostetler (Partner, Wilson Sonsini). |
| UCSF Neuroscience, 675 Nelson Rising Lane, Sandler Neurosciences Ctr, San Francisco |
|
Feb 07 (Wed) @ 09:00 AM
| |
$35 |
|
|
|
|
|
|
|
|
| |
/-122.39237976,37.76922989,13,0,0/550x200?access_token=pk.eyJ1IjoiZ2FyeXNndWlkZSIsImEiOiJjamtobmRiYmgwb3gwM3F1a2o2Mmd0YWw3In0.DinA62CR3-OKtf3axa5O7Q)
|
| |
| DETAILS |
|
Invest in Cures 2024 - A Disease Foundation Forum
Join us to explore the rising trend of impact investing in addressing rare disease challenges through foundations & innovative collaborations including AI in rare diseases. Learn from foundation leaders, advocates & entrepreneurs as they share their perspectives on venture philanthropy for accelerating the commercialization of new therapies & cures for patients.
Invest in Cures combines main stage sessions & panel discussions with intimate gatherings & high-level networking. It is an opportunity for researchers, clinicians & investment professionals from leading foundations to discuss innovative approaches to supporting & funding translational research & drug development.
Capacity is limited & guests must pre-register to attend.
Early-bird registration ends January 8, 2024
ONE ON ONE MATCHMAKING OPPORTUNITIES
California Life Sciences, in collaboration with LaunchBio, is dedicated to creating opportunities for startups & small companies to connect with disease foundations, corporate partners, & other funding sources for new rare disease therapies To that end, selected companies can apply by January 26, 2024 to meet virtually with the following organizations to discuss partnering opportunities.
We invite you to apply to meet with the following organizations (virtually) to discuss partnering opportunities, many of which will be attending the in-person event taking place February 7, 2024, in San Francisco.
Brain Tumor Investment Fund
Chiesi Global Rare Diseases
Cystic Fibrosis Foundation Fund
Multiple Myeloma Fund
Pathway To Cures
Retinal Degeneration Fund (Foundation Fighting Blindness)
Taking place on Feb 6th is UCSF's Rare Disease Symposium: Catalyzing Innovation & Bridging Gaps in Rare Diseases. The event highlights translational research & innovative start-ups focused on rare eye diseases & epilepsies.
To register for the symposium, please navigate here.
AGENDA
8:00am: Coffee, Continental Breakfast, Networking
9:00am: Welcome & Introductions, Thank You to Sponsors
9:05-9:25am: Opening Keynote: Six Guiding Principles to Drive Innovation
9:30-10:30am: Panel 1 - Venture Philanthropy 2.0: Advancements in Disease Foundation Funding
10:35-11:35am: Panel 2 - Panel 4 - Visionary Innovations in Rare Disease: Unveiling Tomorrow's Solutions
11:35am-1:00pm: Lunch Break & Networking
1:00-2:00pm: Panel 3 - Accelerating Hope: The AI Revolution in Rare Disease Drug Development
2:05-2:55pm: Panel 4 - Investing In Patient Outcomes: Early Investments to Empower Innovation
SESSIONS
9:05am: Opening Keynote: Six Guiding Principles to Drive Innovation
Considering that 90% of people living with rare diseases have no treatment, innovation is at the heart of improving patient outcomes. Numerous innovation theories attempt to unravel the various elements of innovation but these theories are often complex, varied in nature, & difficult to apply to rare disease. We need to improve the success rate of rare disease innovation because most new ventures do not generate effective therapies.
Renowned tech innovator, physician, scientist, & devoted rare disease advocate, Dr. James Levine will distill theories on innovation to their core commonalities. There are six critical innovation principles that can be employed to make your venture more successful. Join us & learn what they are.
James Levine, PhD, MD, President, Fondation Ipsen
9:30 - 10:30am: Panel 1
Venture Philanthropy 2.0: Advancements in Disease Foundation Funding
Disease foundations have increasingly taken the leap into the investment world by creating affiliated venture philanthropy or impact investment funds to invest in start-ups with promising technology that address unmet patient needs. This model has proven to be successful with numerous high-value exits & novel treatments for patient populations. As the funds continue to develop & learn from the past, they are taking new approaches to how they invest in companies.
Learn from a diverse group of disease foundation investors, including the originators, early adopters & new funds as they share their perspectives on the latest trends in investing, collaborations & syndications. Learn best practices for working with the foundations they support & the start-ups that receive investment.
Enrique Lin Shiao, PhD, Principal, Ventures Investment, Cystic Fibrosis Foundation
Rusty Kelley, PhD, MBA, Managing Director, Retinal Degeneration Fund (Foundation Fighting Blindness)
Michael Kelly, PhD, Chief Scientific Officer, CureDuchenne
Bernice Martin Lee, CEO, Epilepsy Foundation
Moderator - Mike Hostetler, JD, PhD, Partner, Wilson Sonsini
10:35-11:35am: Startup Showcase
Visionary Innovations in Rare Disease: Unveiling Tomorrow's Solutions
Meet four high-potential start-ups with groundbreaking technology that have the potential to revolutionize the treatment landscape for rare eye diseases & rare epilepsies. This showcase highlights each company's transformative science & unique approaches to addressing the unmet needs of patients suffering from these conditions.
Robert Bhisitkul, MD, Co-Founder & CMO, Oculinea
Daniel Chung, MD, CMO, Sparing Vision
Wesley Jones, MS, MBA, Co-Founder & CEO, Vonova
Chris Reyes, PhD, Co-Founder & CEO, Bloom Science
Emcee: Tyler Mizenko, MBA, VP of Relationships & Business Development, Prendio & BioProcure
1:00-2:00pm: Panel 2
Accelerating Hope: The AI Revolution in Rare Disease Drug Development
Often characterized by limited patient populations & unique challenges, rare diseases present a compelling use case for AI's transformative capabilities. With the capacity to accelerate diagnosis, drug development & commercialization, this revolutionary technology offers hope to the many thousands of patients with rare conditions in their race against time to find a treatment. This panel brings together experts, innovators & thought leaders to explore the promising intersection of AI & rare disease treatment. Learn from industry experts on how to effectively harness the power of AI in drug discovery by asking the right questions, leveraging quality data & understanding how to effectively incorporate this tool into a more holistic drug discovery strategy.
Claire Aldridge, PhD, Chief Strategy Officer, Form Bio
Jeff Milton, Founder & CEO, La Jolla Labs
Stephanie Oestreich, PhD, MPA, Managing Director, Myeloma Investment Fund
Moderator - Marina Sirota, PhD, Associate Professor, Bakar Computational Health Sciences Institute, UCSF
2:05-2:55pm: Panel 3
Investing In Patient Outcomes: Early Investments to Empower Innovation
The mission of a disease foundation venture fund, like that of the parent organization, is to improve patient outcomes & advance treatments for unmet medical needs. These funds are often willing to take on more risk & invest earlier than other types of venture capital investors. By leveraging the wealth of expertise of the affiliated foundations, start-ups can get to an inflection point that attracts follow-on investments. This discussion examines the relationship between disease foundation funds & their portfolio companies, shares examples of deal structures & highlights the commitment of the fund to the success of the portfolio company.
John Higgins, Managing Director, Brain Tumor Investment Fund
Robert Bell, PhD, Founder & CEO, Telo Therapeutics
Robert Blazej, PhD, Partner, Mission BioCapital
Stephanie Oestreich, PhD, MPA, Managing Director, Myeloma Investment Fund
Moderator - Luke Gruenert, Associate Director, Strategic Innovation, Chiesi Global Rare Diseases
|
|
|
|
|
|
|
|
